| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/06/2005 | CA2546199A1 Extended release pharmaceutical dosage form |
| 05/06/2005 | CA2544291A1 Transdermal drug delivery method and system |
| 05/06/2005 | CA2544086A1 Use of a deoxynojirimycin derivative or a pharmaceutically salt thereof |
| 05/06/2005 | CA2543870A1 Therapeutic use of methionine for the treatment or prevention of mucositis |
| 05/06/2005 | CA2543805A1 Processes for preparation of ziprasidone |
| 05/06/2005 | CA2543789A1 Detection of mutations in a gene associated with resistance to viral infection, oas1 |
| 05/06/2005 | CA2543644A1 Pyrazine derivatives and pharmaceutical use thereof |
| 05/06/2005 | CA2543628A1 Multiple active agents such as anthelmintics sustained release delivery |
| 05/06/2005 | CA2543626A1 Synbiotic composition for infants |
| 05/06/2005 | CA2543606A1 Resolution of 3-amino alkylnitriles |
| 05/06/2005 | CA2543570A1 Acylurea connected and sulfonylurea connected hydroxamates |
| 05/06/2005 | CA2543555A1 Therapeutic agent for keratoconjunctival disorder |
| 05/06/2005 | CA2543552A1 Use of neurokinin antagonists in the treatment of urinary incontinence |
| 05/06/2005 | CA2543498A1 Use of hydroxylated amino acids for treating diabetes |
| 05/06/2005 | CA2543419A1 Ccr3 receptor antagonists |
| 05/06/2005 | CA2543404A1 Novel inhibitor of the formation of advanced glycation end product and aldose reductase inhibitor |
| 05/06/2005 | CA2543342A1 Combination treatment of obesity involving 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity and lipase inhibitors |
| 05/06/2005 | CA2543338A1 Novel medical uses of compounds showing cb1-antagonistic activity and combination treatment involving said compounds |
| 05/06/2005 | CA2543319A1 Methods of treating leukemia with suberoylanilide hydroxamic acid |
| 05/06/2005 | CA2543318A1 Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto |
| 05/06/2005 | CA2543312A1 Methods and compositions comprising thalidomide for treatment of fibromyalgia |
| 05/06/2005 | CA2543305A1 Ache antisense deoxyoligonucleotide as an anti-inflammatory agent |
| 05/06/2005 | CA2543287A1 Benzazepine derivatives as mao-b inhibitors |
| 05/06/2005 | CA2543197A1 Combination treatment of obesity involving selective cb1-antagonists and lipase inhibitors |
| 05/06/2005 | CA2543079A1 Dicationic triaryl analogs as anti-protozoan agents |
| 05/06/2005 | CA2543008A1 Methods for the preparation of {2-[8,9-dioxo-2,6-diaza-bicyclo[5.2.0]-non-1(7)-en-2-yl]ethyl}phosphonic acid and esters thereof |
| 05/06/2005 | CA2543002A1 Method for inducing a specific rnai activity in cells and nucleic acids for carrying out said method |
| 05/06/2005 | CA2542996A1 Immunemodulating oligosaccharides |
| 05/06/2005 | CA2542967A1 Inosine monophosphate dehydrogenase inhibitors as phosphonate derivatives |
| 05/06/2005 | CA2542963A1 Inhibitors of cathepsin s |
| 05/06/2005 | CA2542942A1 Nucleic acids useful for triggering tumor cell lethality |
| 05/06/2005 | CA2542913A1 Oligopeptides as coating material for medical products |
| 05/06/2005 | CA2542816A1 N-thiazol-2-yl-benzamide derivatives |
| 05/06/2005 | CA2542804A1 Preparation of lipid particles |
| 05/06/2005 | CA2542720A1 Azabenzodiazepines as phosphodiesterase-4 inhibitors |
| 05/06/2005 | CA2542716A1 Compounds having crth2 antagonist activity |
| 05/06/2005 | CA2542708A1 Dna delivery with gemini cationic surfactants |
| 05/06/2005 | CA2542695A1 Substituted benzylaminoalkylene heterocycles |
| 05/06/2005 | CA2542682A1 5-substituted 2-(phenylmethyl) thio-4-phenyl-4h-1,2,4-triazole derivatives and related compounds as gaba-agonists for the treatment of urinary incontinence and related diseases |
| 05/06/2005 | CA2542661A1 Methods and compositions for treating cancer |
| 05/06/2005 | CA2542522A1 4-(pyrazol-3-ylamino) pyrimidine derivatives for use in the treatment of cancer |
| 05/06/2005 | CA2542514A1 Pyrimidine compounds for the treatment of inflammation |
| 05/06/2005 | CA2542494A1 Tetrahydro-naphthalene and urea derivatives |
| 05/06/2005 | CA2542434A1 Combination of flupirtine and tolperisone or eperisone for the treatment of painful conditions |
| 05/06/2005 | CA2542419A1 Use of glutamyl cyclase inhibitors in the treatment of familial british dementia and familial danish dementia |
| 05/06/2005 | CA2542235A1 Methods, compositions, and kits for organ protection during systemic anticancer therapy |
| 05/06/2005 | CA2542226A1 Novel diazaspiroalkanes and their use for treatment of ccr8 mediated diseases |
| 05/06/2005 | CA2542217A1 Method of administering cationic liposomes comprising an active drug |
| 05/06/2005 | CA2542210A1 Polymorphic form of n-[(r)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide |
| 05/06/2005 | CA2542064A1 Tao kinase modulators and methods of use |
| 05/06/2005 | CA2541994A1 Solid-state montelukast |
| 05/06/2005 | CA2541991A1 Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin d compounds |
| 05/06/2005 | CA2541990A1 Oral formulation of lipid soluble thiamine, lipoic acid, creatine derivative, and l-arginine .alpha.-ketoglutarate |
| 05/06/2005 | CA2541989A1 P70s6 kinase modulators and method of use |
| 05/06/2005 | CA2541894A1 Amino alcohol derivative, medicinal composition containing the same, and use of these |
| 05/06/2005 | CA2541690A1 Glutamine fructose-6-phosphate amidotransferase (gfat) inhibitors |
| 05/06/2005 | CA2541472A1 Dihydrobenzofuranyl alkanamines and methods for using same as cns agents |
| 05/06/2005 | CA2541460A1 Indolinone derivatives and their use in treating disease-states such as cancer |
| 05/06/2005 | CA2541123A1 Compositions and methods comprising prostaglandin-related compounds and trefoil factor family peptides for the treatment of glaucoma with reduced hyperemia |
| 05/06/2005 | CA2541097A1 Biomarkers for the prediction of drug-induced diarrhoea |
| 05/06/2005 | CA2541090A1 Use of indole acetic acid or derivatives thereof to increase igf-1 serum levels |
| 05/06/2005 | CA2540817A1 Diazabicyclononene and tetrahydropyridine derivatives as renin inhibitors |
| 05/06/2005 | CA2540782A1 Diazabicyclononene derivatives and their use as renin inhibitors |
| 05/06/2005 | CA2540765A1 Pyrimidin-2-amine derivatives and their use as a2b adenosine receptor antagonists |
| 05/06/2005 | CA2540543A1 Tetrahydropyridine derivatives |
| 05/06/2005 | CA2540022A1 A polymorphic form of 3-phenylsulfonyl-8-piperazin-1-yl-quinoline |
| 05/06/2005 | CA2539967A1 Amides that inhibit vanilloid receptor subtype 1 (vr1) receptor |
| 05/06/2005 | CA2539845A1 Methods and compositions for treating erectile dysfunction |
| 05/06/2005 | CA2539726A1 4-azole substituted imidazole compositions useful as inhibitors or c-met receptor tyrosine kinase |
| 05/06/2005 | CA2539720A1 1-.prime.(e)-2-(phenyl) ethenyl-4-(arylalkoxy)-oxazole or - thiazole compounds as her-2 tyrosine kinases inhibitors and their use in the treatment of cancer |
| 05/06/2005 | CA2539277A1 Aminoalkanol derivatives |
| 05/06/2005 | CA2538630A1 Novel compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them |
| 05/06/2005 | CA2538134A1 Novel imidazole derivatives and their use as pharmaceutical agents |
| 05/06/2005 | CA2538131A1 Novel triarylimidazoles |
| 05/06/2005 | CA2537224A1 Heterocycle-substituted pteridine derivatives and their use in therapy |
| 05/06/2005 | CA2536535A1 Compounds and compositions as protein kinase inhibitors |
| 05/06/2005 | CA2534996A1 The use of sirna silencing in the prevention of metastasis |
| 05/06/2005 | CA2534828A1 Novel cxcl8 antagonists |
| 05/06/2005 | CA2532094A1 Sp1 and sp3 targeted cancer therapies and therapeutics |
| 05/06/2005 | CA2528805A1 Gsk-3 inhibitors and uses thereof |
| 05/06/2005 | CA2526804A1 Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity |
| 05/05/2005 | US20050097628 Terminological mapping |
| 05/05/2005 | US20050096485 Thyronamine derivatives and analogs and methods of use thereof |
| 05/05/2005 | US20050096484 Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders |
| 05/05/2005 | US20050096479 Novel succinate salt of O-desmethyl-venlafaxine |
| 05/05/2005 | US20050096473 Reacting 1,1'-thiocarbonyldiimidazole with an aryl amine, e.g., benzylamine, to form 1830 thiourea (or urea)prodoucts; high speed, automatic process; anticarcinogenic agents, leukemia; enzyme inhibitors for HIV reverse transcriptase (polymerase) |
| 05/05/2005 | US20050096469 Mono-ester and asymmetrically substatuted di-ester pro-drugs of dopamide d1 receptor agonists |
| 05/05/2005 | US20050096468 Inhibitors of histone deacetylase |
| 05/05/2005 | US20050096463 Metastasis inducing DNA's |
| 05/05/2005 | US20050096460 Beta-amyloid peptide-binding proteins and polynucleotides encoding the same |
| 05/05/2005 | US20050096397 Adding trifluoroacetic acid dropwise to a solution of dimethylphenylsilane and (S)-amino-1-(2,5-dimethoxy-phenyl)-1-propanone, the amino group of which is protected, for example, with a methoxycarbonyl group; reduction; deprotecting; salt formation |
| 05/05/2005 | US20050096396 Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning |
| 05/05/2005 | US20050096395 Norepinephrine-serotonin reuptake inhibitor (NSRI) compound to treat attention deficit/hyperactivity disorder and Tic disorder; NSRI compound has a NE:5-HT reuptake inhibition ratio of between 1:1 and 10:; milnacipran |
| 05/05/2005 | US20050096393 incorporating one or more preservatives in a mildly acidic aqueous solution; include organic acids and the salts and esters, free from preservatives which can generate sulfur or chlorine-containing compounds; nontoxic |
| 05/05/2005 | US20050096392 Use of creatine pyruvate for increasing stamina during highly intensive intermittent physical exertion |
| 05/05/2005 | US20050096391 Particulate or in solid dosage forms; a combination of fenofibrate and HMG CoA reductase inhibitor rosuvastatin or a pharmaceutically active salts, upon oral administration provides a relative AUC0-24 value (AUCfibric acid/AUCrosuvastatin) of between 150 to 12,000 |
| 05/05/2005 | US20050096390 Compositions comprising fenofibrate and pravastatin |
| 05/05/2005 | US20050096388 Compositions and methods for treating or preventing diseases of body passageways |
| 05/05/2005 | US20050096383 Method and composition for oral cavity hygiene |
| 05/05/2005 | US20050096382 Agent for preventing recurrence of cerebrovascular disorder and agent for ameliorating troubles following cerebrovascular disorder and inhibiting progress thereof |